Median age was 77 yr (interquartile range [IQR]: 73–80 yr), median baseline prostate-specific antigen (PSA) was 56 ng/ml (IQR: 30–112), and 43% (32 of 74) had metastatic disease. Here, KLK3 is linked to metastatic neoplasm.